Menu

Close

Advances in Drug Delivery

Advances in formulation technology or targeted delivery methods that describe or develop the distribution of small molecules or large macromolecules to specific parts of the body.

List by Zhang-He Goh

Preprints:

Physicochemical characterization, toxicity and in vivo biodistribution studies of a discoidal, lipid-based drug delivery vehicle: Lipodisq nanoparticles containing doxorubicin

Maria L Torgersen, Peter J Judge, Juan F Bada Juarez, Abhilash D Pandya, Markus Fusser, Charlie W Davies, Matylda K Maciejewska, Daniel J Yin, Gunhild M Maelandsmo, Tore Skotland, Anthony Watts, Kirsten Sandvig

https://www.biorxiv.org/content/10.1101/2020.06.18.159087v1

Doxorubicin is an anticancer agent that exhibits poor pharmacokinetics and significant toxicities. As such, administration of doxorubicin to patients has often proved a clinical challenge. Torgersen et al. describe a new formulation approach to resolve this problem–in the form of Lipodisq nanoparticles, a hydrolysed co-polymer of styrene and maleic anhydride (SMA).

Engineering Brain Parasites for Intracellular Delivery of Therapeutic Proteins

Shahar Bracha, Karoliina Hassi, Paul D. Ross, Stuart Cobb, Lilach Sheiner, Oded Rechavi

https://www.biorxiv.org/content/10.1101/481192v1

The delivery of drugs across the blood-brain barrier is a challenge to chemists and pharmacologists. In this preprint, Bracha et al. describe an unconventional approach: the authors use engineered brain parasites to achieve directed intracellular therapy of proteins to the central nervous system.

Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies

Candice Gurbatri, Courtney Coker, Taylor E. Hinchliffe, Ioana Lia, Samuel Castro, Piper M. Treuting, Nicholas Arpaia, Tal Danino

https://www.biorxiv.org/content/10.1101/562785v1

For over a decade, the microbiome has attracted the attention of pharmacologists, who have come to recognise the potential role that the microbiome plays in the metabolism and delivery of therapeutics. In this preprint, Gurbatri et al. exploit this interesting feature in bacteria, turning it into a warhead that can deliver immunotherapies–specifically, PD-L1 antagonists.

Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity

S. Pieper, H. Onafuye, D. Mulac, Jindrich Cinatl jr., Mark N. Wass, M. Michaelis, K. Langer

https://www.biorxiv.org/content/10.1101/403923v1

Based on the preliminary results offered by this preprint by Pieper et al., formulators can subject formulations to a more rigorous and systematic process of optimisation over a larger range of conditions, pharmacokineticists can profile the behaviour of these nanoparticle formulations in vitro and in vivo, and, once the effectiveness and safety of these drug delivery systems are demonstrated in animal models, clinician-scientists can run in-human trials on patients who stand to gain from these drug delivery systems.

Organ-restricted vascular delivery of nanoparticles for lung cancer therapy

Deniz A. Bölükbas, Stefan Datz, Charlotte Meyer-Schwickerath, Carmela Morrone, Ali Doryab, Dorothee Gößl, Malamati Vreka, Lin Yang, Christian Argyo, Sabine H. van Rijt, Michael Lindner, Oliver Eickelberg, Tobias Stoeger, Otmar Schmid, Sandra Lindstedt, Georgios T. Stathopoulos, Thomas Bein, Darcy E. Wagner, Silke Meiners

https://www.biorxiv.org/content/10.1101/2020.03.05.969212v1

Bolukbas et al. apply nanotherapy to pulmonary therapy–by utilising mesoporous silica nanoparticles to improve targeted delivery through the enhanced permeability and retention (EPR) effect. The authors illustrate this distribution using a murine lung tumour model.

Categories: pharmacology and toxicology , synthetic biology

 

Posted on: 20th May 2019 , updated on: 21st June 2020

(No Ratings Yet)




  • Have your say

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Sign up to customise the site to your preferences and to receive alerts

    Register here

    Also in the pharmacology and toxicology category:

    COVID-19 / SARS-CoV-2 preprints

    List of important preprints dealing with the ongoing coronavirus outbreak. See http://covidpreprints.com for additional resources and timeline, and https://connect.biorxiv.org/relate/content/181 for full list of bioRxiv and medRxiv preprints on this topic

     



    List by Gautam Dey, Zhang-He Goh

    1

    Drug use in special populations

    Any drugs that are being used in special populations: Patients with liver and kidney failure, in paediatrics, in geriatrics, and in pregnant or lactating patients. Includes the discovery of factors that could potentially affect drug use in these special populations.

     



    List by Zhang-He Goh

    Toxicology of toxicants, existing therapeutics, and investigational drugs

    Preprints that describe the toxicology of environmental pollutants and existing and upcoming drugs. Includes both toxicokinetics and toxicodynamics, as well as technological improvements that will help in the characterisation of this field.

     



    List by Zhang-He Goh

    Antimicrobials: Discovery, clinical use, and development of resistance

    Preprints that describe the discovery of new antimicrobials and any improvements made regarding their clinical use. Includes preprints that detail the factors affecting antimicrobial selection and the development of antimicrobial resistance.

     



    List by Zhang-He Goh

    Anticancer agents: Discovery and clinical use

    Preprints that describe the discovery of anticancer agents and their clinical use. Includes both small molecules and macromolecules like biologics.

     



    List by Zhang-He Goh
    Close